TrialDiabetes2021

The Deterrence of Rapid Metabolic Decline Within 3 Months After Teplizumab Treatment in Individuals at High Risk for Type 1 Diabetes.

Emily K Sims et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.